Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

por Cao, Xin-xin, Jin, Jie, Fu, Cheng-cheng, Yi, Shu-hua, Zhao, Wei-li, Sun, Zi-min, Yang, Wei, Li, Deng-ju, Cui, Guo-hui, Hu, Jian-da, Liu, Ting, Song, Yong-ping, Xu, Bing, Zhu, Zun-min, Xu, Wei, Zhang, Ming-zhi, Tian, Ya-min, Zhang, Bin, Zhao, Ren-bin, Zhou, Dao-bin
Publicado 2022

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

por Deng, Li-Juan, Zhou, Ke-Shu, Liu, Li-Hong, Zhang, Ming-Zhi, Li, Zhi-Ming, Ji, Chun-Yan, Xu, Wei, Liu, Ting, Xu, Bing, Wang, Xin, Gao, Su-Jun, Zhang, Hui-Lai, Hu, Yu, Li, Yan, Cheng, Ying, Yang, Hai-Yan, Cao, Jun-Ning, Zhu, Zun-Min, Hu, Jian-Da, Zhang, Wei, Jing, Hong-Mei, Ding, Kai-Yang, Zhang, Xiang-Yang, Zhao, Ren-Bin, Zhang, Bin, Tian, Ya-Min, Song, Yong-Ping, Song, Yu-Qin, Zhu, Jun
Publicado 2023